Table 2.

Univariate and multivariate analysis for PFS and OS according to BRCA1/2 aberrations

Variables	Univariate analysis				Multivariate analysisa
	PFS		OS		PFS		OS
	HR (95% CI)	P b	HR (95% CI)	P b	HR (95% CI)	P b	HR (95% CI)	P b
Entire cohort (n = 2636)
Age	—	—	—	—	1.10 (1.00 to 1.25)	.05	1.22 (1.10 to 1.37)	<.001
Grade	—	—	—	—	2.38 (1.84 to 3.07)	<.001	1.80 (1.35 to 2.41)	<.001
Stage	—	—	—	—	2.89 (2.36 to 3.47)	<.001	2.76 (2.19 to 3.48)	<.001
Residual disease	—	—	—	—	1.59 (1.41 to 1.80)	<.001	1.79 (1.57 to 2.03)	<.001
BRCA1 methylation	1.01 (0.87 to 1.16)	.98	1.02 (0.87 to 1.18)	.96	1.01 (0.88 to 1.15)	.92	1.00 (0.86 to 1.17)	.97
Cohort with known BRCA1/2 mutations (n = 1248)
Age	—	—	—	—	1.08 (0.93 to 1.25)	.33	1.18 (1.00 to 1.37)	.04
Grade	—	—	—	—	2.30 (1.48 to 3.57)	<.001	1.97 (1.19 to 3.27)	.01
Stage	—	—	—	—	4.07 (3.00 to 5.52)	<.001	3.10 (2.18 to 4.42)	<.001
Residual disease	—	—	—	—	1.37 (1.15 to 1.62)	<.001	1.54 (1.29 to 1.83)	<.001
BRCA1 methylation	1.26 (1.02 to 1.56)	.03	1.11 (0.88 to 1.41)	.35	1.06 (0.85 to 1.34)	.59	0.97 (0.75 to 1.24)	.78
BRCA1 mutation	0.99 (0.80 to 1.23)	.91	0.87 (0.69 to 1.10)	.24	0.78 (0.62 to 0.99)	.04	0.76 (0.58 to 0.98)	.03
BRCA2 mutation	0.58 (0.43 to 0.77)	<.001	0.57 (0.41 to 0.80)	<.001	0.51 (0.37 to 0.69)	<.001	0.51 (0.35 to 0.73)	<.001

^aAll clinical variables within the multivariate model are binary, as follows: Age: 0 for <60 (median age) and 1 for ≥60; Grade: 0 for low grade, 1 for high grade; 0 for stage I/II, 1 for stage III/IV; Residual disease: 0 for <1 cm, 1 for ≥1 cm. CI = confidence interval; HR = hazard ratio; OS= overall survival; PFS = progression-free survival.

^bTwo-tailed mixed-effects Cox proportional hazards regression model with P value adjusted for study.